BVNKF Company Profile and Key Details

Bavarian Nordic A/S earnings surprise history is a mixed track record. The quarter that ended March 12, 2026, missed forecasts by -9.71%. The prior quarter beat by 68.81%. Over the last six quarters, Apple has recorded several small beats. These include 72.74% in June 28, 2024.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

The stock is currently trading near its 52-week low $27.69 and $37.22. With a market capitalization of about $2.14 billion, Bavarian Nordic A/S is classified as a mid-cap and shows market-like volatility (beta ~0.94). Key stats such as the average daily volume over the past year has been around 109.00 shares, in line with its 52-week average. Headquartered in Hellerup, CR, Bavarian Nordic A/S operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul Chaplin, the company employs approximately 1,795 people and listed since October 15, 2010. Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases.

Our AI price prediction model suggests that Bavarian Nordic A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Bavarian Nordic A/S trading at a premium to the broader market with a P/E of 12.29.

Bavarian Nordic A/S trades at a P/E ratio of 12.29, slightly below the S&P 500 average, with a price-to-sales ratio of 2.34 and a price-to-book ratio of 1.09 suggesting the stock is closer to book value. The P/FCF stands at 10.08, also below market averages.